CPRX is a biopharmaceutical company that develops therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It has now entered the advanced stage with strong financial performance.
Strong Points:
- Formed breakaway gap which kicked off the advance stage upon announcement of impressive results.
- Post-quarter revenues increased 23% while earnings jumped 64%
- Future growth is expected to be above 40% which will keep driving its price upside
Risk:
A temporary pullback may occur